Altera in negotiation on private equity partner
Intel expects to see a partnership with private equity on the spin out of its Altera FPGA business later this year.
By Nick Flaherty, eeNews Europe (April 26, 2024)
The FPGA division saw revenue down in the first quarter as a result of excess inventories highlighted by CEO Sandra Rivera, see: CEO interview: Sandra Rivera of Altera on the move to Intel 18A
“This quarter, we formally rebranded our Programmable Solutions Group, “Altera, an Intel Company,” said Dave Zinsner, Intel chief financial officer. “We look forward to bringing in a private equity partner this year to help prepare the company for an IPO in the coming years.”
![]() |
E-mail This Article | ![]() |
![]() |
Printer-Friendly Page |
Related News
- Altera Launches New Partner Program to Accelerate FPGA Solutions Development
- NXP and Chinese Private Equity firm JianGuang Asset Management to Establish Semiconductor Joint Venture
- Fuji Xerox Recognizes Altera with 2014 Premier Partner Award
- BittWare and PLDA Partner to Deliver 10G Low Latency TCP Offload, UDP and PCIe IP Cores on Altera Stratix-based Hardware
- Huawei Names Altera 2012 Excellent Core Partner for Delivering Quality, Leading-edge Products and Superior Technical Support
Breaking News
- RISC-V International Promotes Andrea Gallo to CEO
- See the 2025 Best Edge AI Processor IP at the Embedded Vision Summit
- Andes Technology Showcases RISC-V AI Leadership at RISC-V Summit Europe 2025
- RISC-V Royalty-Driven Revenue to Exceed License Revenue by 2027
- Keysom Unveils Keysom Core Explorer V1.0
Most Popular
- RISC-V Royalty-Driven Revenue to Exceed License Revenue by 2027
- SiFive and Kinara Partner to Offer Bare Metal Access to RISC-V Vector Processors
- Imagination Announces E-Series: A New Era of On-Device AI and Graphics
- Siemens to accelerate customer time to market with advanced silicon IP through new Alphawave Semi partnership
- Cadence Unveils Millennium M2000 Supercomputer with NVIDIA Blackwell Systems to Transform AI-Driven Silicon, Systems and Drug Design